These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7791066)

  • 21. Low-dose tissue plasminogen activator in the management of anterior chamber fibrin formation.
    Georgiadis N; Boboridis K; Halvatzis N; Ziakas N; Moschou V
    J Cataract Refract Surg; 2003 Apr; 29(4):729-32. PubMed ID: 12686240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery.
    Siatiri H; Beheshtnezhad AH; Asghari H; Siatiri N; Moghimi S; Piri N
    Br J Ophthalmol; 2005 Nov; 89(11):1458-61. PubMed ID: 16234453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue plasminogen activator for postvitrectomy fibrin formation.
    Jaffe GJ; Abrams GW; Williams GA; Han DP
    Ophthalmology; 1990 Feb; 97(2):184-9. PubMed ID: 2109297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrinolysis of postcataract fibrin membranes in children.
    Mehta JS; Adams GG
    J Cataract Refract Surg; 2000 Jan; 26(1):4-5. PubMed ID: 10646131
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy].
    Zhao P; Wang W
    Zhonghua Yan Ke Za Zhi; 1995 Jul; 31(4):255-8. PubMed ID: 8745515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of fibrinous effusion.
    Starck T
    J Cataract Refract Surg; 1998 May; 24(5):575. PubMed ID: 9610435
    [No Abstract]   [Full Text] [Related]  

  • 27. Intraocular tissue plasminogen activator in a rabbit model of traumatic hyphema.
    Howard GR; Vukich J; Fiscella RG; Farber MD; Goldberg MF
    Arch Ophthalmol; 1991 Feb; 109(2):272-4. PubMed ID: 1899562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracameral tissue plasminogen activator for treatment of excessive fibrin response after penetrating keratoplasty.
    Snyder RW; Sherman MD; Allinson RW
    Am J Ophthalmol; 1990 Apr; 109(4):483-4. PubMed ID: 2109930
    [No Abstract]   [Full Text] [Related]  

  • 29. Intracameral recombinant tissue plasminogen activator (r-tPA) for refractory toxic anterior segment syndrome.
    Dotan A; Kaiserman I; Kremer I; Ehrlich R; Bahar I
    Br J Ophthalmol; 2014 Feb; 98(2):252-5. PubMed ID: 24276695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery.
    Wedrich A; Menapace R; Ries E; Polzer I
    J Cataract Refract Surg; 1997; 23(6):873-7. PubMed ID: 9292671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of tissue plasminogen activator in postvitrectomy cases.
    Koutsandrea C; Apostolopoulos M; Theodossiadis P
    Int Ophthalmol; 1993 Apr; 17(2):95-100. PubMed ID: 8407122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The lowest effective dose of tissue plasminogen activator for fibrinolysis of postvitrectomy fibrin.
    Boldt HC; Abrams GW; Murray TG; Han DP; Mieler WF
    Retina; 1992; 12(3 Suppl):S75-9. PubMed ID: 1455089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic and prophylactic application of TPA (recombinant tissue plasminogen activator) into the anterior chamber of the eye].
    Rehfeldt K; Höh H
    Ophthalmologe; 1999 Sep; 96(9):587-93. PubMed ID: 10501987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three cases of corneal perforation caused by noncontact tonometry.
    Kim EC; Kim MS
    Cornea; 2008 Dec; 27(10):1191-4. PubMed ID: 19034141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrinolysis of postcataract fibrin membranes in children.
    Leung AT; Lam DS; Rao SK
    J Cataract Refract Surg; 2000 Jan; 26(1):4; author reply 5. PubMed ID: 10646130
    [No Abstract]   [Full Text] [Related]  

  • 36. Tissue plasminogen activator in the treatment of vitreoretinal diseases.
    Kamei M; Estafanous M; Lewis H
    Semin Ophthalmol; 2000 Mar; 15(1):44-50. PubMed ID: 10749314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topical treatment of postvitrectomy fibrin formation with tissue plasminogen activator.
    Cellini M; Baldi A; Possati GL
    Int Ophthalmol; 1994-1995; 18(6):351-3. PubMed ID: 7642335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indications for penetrating keratoplasty and associated procedures, 1989-1995.
    Lois N; Kowal VO; Cohen EJ; Rapuano CJ; Gault JA; Raber IM; Laibson PR
    Cornea; 1997 Nov; 16(6):623-9. PubMed ID: 9395870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of tissue plasminogen activator on retinal bleeding.
    Sternberg P; Aguilar HE; Drews C; Aaberg TM
    Arch Ophthalmol; 1990 May; 108(5):720-2. PubMed ID: 2110447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue plasminogen activator treatment of postoperative intraocular fibrin.
    Johnson RN; Olsen K; Hernandez E
    Ophthalmology; 1988 May; 95(5):592-6. PubMed ID: 3140157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.